الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 206 |  |  |
| | | from | 206 | | |
Abstract
In the present study, allergic airway disease was induced by acute, subacute, chronic 6 wks and chronic 10 wks exposure to OVA albumin mist. Mice were sensitized by single I.P. injection of 10 µg of Grade V chicken egg OVA albumin and 1 mg aluminium potassium sulfate (adjuvant) in 0.5 ml saline (acute and subacute exposure) or two sensitization on days 0 and 14 ( both chronic exposures). Then mice were challenged by nebulization of 1% (wt/vol) OVA in saline solution on days14-17 (acute model), on days 14–20 (subacute model), or 3 day/week for 6 weeks (chronic 6 wks model) or 3 day/week for 10 weeks (chronic 10 wks model ). The acute and subacute groups showed a significant increase in lung weight index, total cell count, differential cell counts, total nitric oxide in both BAL and homogenate and IL-13. Only subacute group showed a significant increase in homogenate TGF-β1. The chronic 6 wks group had a moderate inflammation, but the chronic 10 weeks group exhibited a very mild inflammation. Both chronic models exhibited marked increase in BAL and homogenate IL-13, collagen content and TGF-β1 in BAL and homogenate together with a decrease in nitric oxide content of homogenate. Moreover, lung and tracheal histopathological examination as subepithelial inflammation, epithelial wall thickness, basement membrane thickness, peribronchial fibrosis score and goblet cell hyperplasia were conducted.
In the current study, the possible activity of the anti-asthma medications; Beclomethasone, Montelukast sodium and Tranilast on the sequence of events in airway remodeling of asthmatic mice was evaluated.
The current study concluded that, the positive results of oral administration of tranilast if it is compared with inhaled beclomethasone and montelukast, highlight the beneficial oral mast cell stabilizers in asthma treatment.
Also it highlights the value of chronic use of anti-leukotriene modifiers (montelukast) in asthma by preventing airway inflammation. To our knowledge this is the first study to document the potential efficacy of tranilast and montelukast on airway remodeling.